Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment
Słowa kluczowe
Abstrakcyjny
Background: Multi-functional design of ligands emerged as new drug design paradigm of Alzheimer's disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcho- linesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively.
Materials and methods: Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE.
Results: The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research.
Conclusion: The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.
Keywords: Chalcones; acetylcholinesterase; flurbiprofen; monoamine oxidase; pharmacophore; rivastigmine..
